| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | January 28, 2025 4:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Save time and jump to the most important pieces.
SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)
SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)
SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)
4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today the appointment of Mr. David H. Deming to the Phio Board of Directors, effective Feb 19, 2025. Mr. Deming will immediately serve as a member of the Board's Nominating Committee. Following the appointment of Mr. Deming, the Board now comprises 6 directors, 5 of whom are independent."Mr. Deming's extensive experience in in the biopharma sector, both through his investme
Marlborough, Massachusetts--(Newsfile Corp. - August 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the quarter ended June 30, 2024 and provided a business update.Recent Corporate UpdatesThe Phase 1b clinical trial for our lead product candidate, PH-762, received a positive safety recommendation from the Safety Monitoring Committee (SMC). There were no dose-limiting toxicities, or clinically relevant treatment-emergent adverse events in the initial cohort receiving intratumora
Marlborough, Massachusetts--(Newsfile Corp. - August 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced the appointment of Robert M. Infarinato to the position of vice president and chief financial officer effective August 1, 2024. He will serve in the capacity of Principal Financial Officer including responsibility for accounting, finance, treasury, investor relations and administration. Mr. Infarinato comes to Phio with more than 20 years of financial and accounting leadership experience. He most recen
-Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in third cohort, permitting escalation in next dose concentrationMarlborough, Massachusetts--(Newsfile Corp. - April 9, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio announced today that the Safety Monitoring Committee (SMC) recommended dose escalation in Phio's Phase 1b clinical trial (NCT 06014086) for Phio's lead product candidate, PH-762.Phio's Phase 1b clinical trial is a multi-center, dose-escalating trial designed to evaluate the safety a
To be presented at 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany Marlborough, Massachusetts--(Newsfile Corp. - April 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biotechnology company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio today announced that podium presentations will be given on its two lead INTASYL product candidates, PH-762 and PH-894. The ITOC conference provides a unique platform for the exchange of latest findings in immunotherapy of cancer to advance oncology drug development and delivery.Melissa Maxwell, Phio's Director of Research and Program Management, w
Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-7623rd Cohort now fully enrolled in on-going clinical studyMarlborough, Massachusetts--(Newsfile Corp. - March 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today reported its financial results for the year ended December 31, 2024, and provided a business update.Recent Corporate UpdatesPH-762 Clinical ProgressPH-762 is currently being evaluated in a U.S. multi-center Phase 1b dose-escalating clinical tri
8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)
10-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)
8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)
HC Wainwright & Co. reiterated coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $6.00 from $4.00 previously
3 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)